Context: The mitral valve conducts blood ﬂow from the left atrium to the left ventricle. Mitral regurgitation occurs when the valve
couldn’t be closed properly at the end of ventricular ﬁlling. Mitraclip, a catheter-based device that can reduce mitral regurgitation
without requiring open surgery, is routinely used for patients with unacceptable risk of conventional mitral valve repair or replacement.
Thepurpose of this study is assessing the safety, eﬃcacy, andeconomicaspects of Mitraclip treatment for mitral regurgitation.
EvidenceAcquisition: TheCochrane Library, theTRIP database, andGoogle Scholar havebeensearchedthroughappropriate strategies.
Seven studies were included in the ﬁnal phase based on the inclusion and exclusion criteria. Data collected from these studies
were analyzed based on four main themes; applications, safety, eﬃcacy, and economic evaluation.
Results: The most potential side eﬀects were related to an improper transfer of catheters and low durability of the device. One of
the included studies showed that improved outcomes of the New York Heart Association (NYHA) was more in the clip group with
better quality of life that were observed after 1 to 12 months in 192 patients and also one-year mortality rate after using clip ranged
between 10% and 24%. This included study found that 72% to 100% of patients with Mitraclip have been successfully treated and the
duration of hospital stays in these patients was between 5 to 10 days. The cost-eﬀectiveness of the procedure still needs more robust
Conclusions: Giventhe lack of high quality evidenceand relatively high cost of Mitraclip, it seems that until further robustevidence
is produced; it should be used in research and in high risk patients selected after detailed examination with strict indications and
appropriate opinions of cardiologists.
<embed src="http://www.test.com/example.pdf" width="500" height="375">